0QDU Stock Overview
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.15 |
| 52 Week High | SEK 0.27 |
| 52 Week Low | SEK 0.15 |
| Beta | 1.26 |
| 11 Month Change | -1.84% |
| 3 Month Change | n/a |
| 1 Year Change | -43.65% |
| 33 Year Change | -78.32% |
| 5 Year Change | n/a |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QDU | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | -43.7% | -20.1% | 6.6% |
Return vs Industry: 0QDU underperformed the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0QDU underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0QDU volatility | |
|---|---|
| 0QDU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QDU's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QDU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Ellen Donnelly | abliva.com |
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children’s Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| 0QDU fundamental statistics | |
|---|---|
| Market cap | SEK 217.60m |
| Earnings (TTM) | -SEK 102.12m |
| Revenue (TTM) | SEK 137.00k |
1,588x
P/S Ratio-2.1x
P/E RatioIs 0QDU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QDU income statement (TTM) | |
|---|---|
| Revenue | SEK 137.00k |
| Cost of Revenue | SEK 72.82m |
| Gross Profit | -SEK 72.68m |
| Other Expenses | SEK 29.44m |
| Earnings | -SEK 102.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.063 |
| Gross Margin | -53,051.09% |
| Net Profit Margin | -74,542.34% |
| Debt/Equity Ratio | 0% |
How did 0QDU perform over the long term?
See historical performance and comparison